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Abstract
Background: A myofascial trigger point is defined as a hyperirritable spot in skeletal muscle that is associated with
a hypersensitive palpable nodule in a taut band. It has been suggested that myofascial trigger points take part in
chronic pain conditions including primary headache disorders. The aim of this narrative review is to present an
overview of the current imaging modalities used for the detection of myofascial trigger points and to review
studies of myofascial trigger points in migraine and tension-type headache.
Findings: Different modalities have been used to assess myofascial trigger points including ultrasound, microdialysis,
electromyography, infrared thermography, and magnetic resonance imaging. Ultrasound is the most promising of
these modalities and may be used to identify MTrPs if specific methods are used, but there is no precise description of
a gold standard using these techniques, and they have yet to be evaluated in headache patients.
Active myofascial trigger points are prevalent in migraine patients. Manual palpation can trigger migraine attacks. All
intervention studies aiming at trigger points are positive, but this needs to be further verified in placebo-controlled
environments. These findings may imply a causal bottom-up association, but studies of migraine patients with
comorbid fibromyalgia syndrome suggest otherwise. Whether myofascial trigger points contribute to an increased
migraine burden in terms of frequency and intensity is unclear.
Active myofascial trigger points are prevalent in tension-type headache coherent with the hypothesis that peripheral
mechanisms are involved in the pathophysiology of this headache disorder. Active myofascial trigger points in pericranial
muscles in tension-type headache patients are correlated with generalized lower pain pressure thresholds indicating they
may contribute to a central sensitization. However, the number of active myofascial trigger points is higher in adults
compared with adolescents regardless of no significant association with headache parameters. This suggests myofascial
trigger points are accumulated over time as a consequence of TTH rather than contributing to the pathophysiology.
Conclusions: Myofascial trigger points are prevalent in both migraine and tension-type headache, but the role they play
in the pathophysiology of each disorder and to which degree is unclarified. In the future, ultrasound elastography may be
an acceptable diagnostic test.
Keywords: Headache, Myofascial trigger point, Muscle, Treatment, Trigemino-cervical-complex, Migraine, Tension-type
headache, Diagnostic test
Background
Migraine affects 16% of the population in Europe [1]
with high individual and socioeconomic costs [2, 3]. Sev-
eral mechanisms have been proposed to be involved in
its pathophysiology including vascular, peripheral and
central mechanisms [4–9]. Jes Olesen systematically de-
scribed pericranial tenderness in migraine patients, both
during and outside of migraine attacks [10, 11], leading
to speculations that myofascial mechanisms may be in-
volved in migraine [12].
Tension-type headache (TTH) is the most prevalent
primary headache disorder worldwide [13]. Tenderness
in pericranial myofascial tissue is correlated with the in-
tensity and frequency of headache in TTH [14–16], and
studies show increased muscle stiffness in TTH patients
[17, 18]. Thus, myofascial structures may be associated
with TTH pathophysiology.
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The term myofascial trigger point (MTrP) was popu-
larized in the 1950s and is defined as a hyperirritable
spot in skeletal muscle that is associated with a hyper-
sensitive palpable nodule in a taut band [19, 20]. The
spot is painful on compression and can cause referred
pain, referred tenderness, motor dysfunction and auto-
nomic phenomena. The interest in myofascial symptoms
has been ongoing for centuries with similar descriptions
of localized thickenings of muscles with regional pain
[21]. There have been inconsistencies and controversies
in the literature on the underlying pathology, and even
the existence of MTrPs [22]. While attempts have been
made to visualize MTrPs [22], the gold standard for de-
tection of MTrPs has been unchanged since the 1950s
[22] and remains to be by way of palpation of the
affected muscles. However, this technique proves to be
poorly reproducible as practitioners disagree on the
location of MTrPs when blindly examining different pa-
tient groups [23]. Nevertheless, MTrPs have come to
play a central role in the diagnosis and treatment of
myofascial pain syndrome [19]. Furthermore, MTrPs
have been proposed to take part in primary headache
disorders and other chronic pain conditions [12]. The
aim of this narrative review is to present an up-to-date
overview on MTrPs in general and then in migraine and
TTH, respectively.
Review
Myofascial trigger points
In the comprehensive trigger point manual by Travell and
Simons [19], MTrPs are subclassified into different types,
e.g., active and latent amongst others. An active MTrP
produces a constant pain complaint while a latent only
produces pain during manual palpation [19]. It was
hypothesized that a sustained muscle contraction in
MTrPs promotes hypoxia and ischemia with a following
increase in concentrations of substances such as calcitonin
gene-related peptide (CGRP) and substance P (SP) [24].
Consequently, this would lead to increased peripheral
nociceptive transmission [24]. This hypothesis is only sup-
ported in active MTrPs, as they have been shown to be as-
sociated with higher levels of these substances in the local
milieu compared to latent MTrPs [25, 26]. Other proper-
ties such as the consistency of the tissue have also been
suggested to play a key role in MTrPs [27].
Investigations of myofascial trigger points
Ultrasound imaging
Different ultrasound modalities in ultrasound imaging
have visualized MTrPs. Lewis et al. [28] conducted a pilot
study to assess the use of ultrasound in determining soft
tissue changes in the region of active MTrPs in 11 sub-
jects. They found no correlation between clinical identified
active MTrPs and ultrasound. In contrast, Turo et al. [29]
were able to differentiate between symptomatic MTrPs
and asymptomatic muscle tissue with texture-based ana-
lysis. Sikdar et al. investigated the stiffness of active and la-
tent MTrPs, using ultrasound elastography by Doppler
variance imaging in nine subjects while inducing
vibrations with an external handheld massage vibrator
[27]. MTrPs appeared as focal, hypoechoic regions on
two-dimensional ultrasound images and with reduced vi-
bration amplitude, indicating increased stiffness. Further-
more, they describe hypoechoic regions that were not
identified during palpation prior to ultrasound. In another
study by the same group, MTrPs showed reduced vibra-
tion amplitude on elastography indicating increased stiff-
ness and distinct blood flow waveform patterns [30].
Ballyns et al. [31] used elastography to investigate MTrPs
in 44 subjects with acute cervical pain. They were able to
measure the size and distinguish type (active, latent) of
MTrPs with elastography. In addition, Doppler waveforms
of blood flow showed different characteristics in active
sites compared to normal tissue. Takla et al. [32] compared
elastography with two-dimensional grayscale ultrasound in
identifying MTrPs. They found that MTrPs had an accur-
acy of 100% for both active and latent MTrPs while
two-dimensional grayscale ultrasound could only identify
33 and 35%, respectively.
Microdialysis
Microdialysis has been used to measure endogenous and
exogenous molecules in the local milieu of MTrPs. Shah
et al. [25] used microdialysis to investigate subjects with
active or latent MTrP, and controls without MTrP were
detected by manual palpation by two experienced clini-
cians. The authors measured selected substances (pH,
bradykinin (BK), CGRP, SP, tumor necrosis factor alpha
(TNF-α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6),
interleukin 8 (IL-8), serotonin, and norepinephrine (NE))
in standardized locations of the trapezius muscle and
gastrocnemius muscle. Subjects with active MTrPs in
the trapezius muscle showed increased concentrations of
all substances compared to the other groups. Shah et al.
[26] found similar results in the trapezius muscle of sub-
jects with neck pain and active MTrP compared to a
group with neck pain and no MTrP present and healthy
controls. The results showed that the active MTrP group
had higher concentrations of BK, CGRP, SP, TNF-α,
IL-1β, serotonin, NE.
Electromyography
Electromyography (EMG) can be used to measure the
electrical activity of skeletal muscles. Simons et al. com-
pared the prevalence of motor endplate potentials in ac-
tive MTrPs, endplate zones, and taut bands of skeletal
muscles in subjects with palpable MTrPs [33]. The au-
thors found that endplate noise was more common in
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MTrPs than in sites outside of the trigger point, even
within the same endplate zone. Ge et al. evaluated intra-
muscular muscle activity in a synergistic muscle during
isometric contraction in 15 subjects with latent MTrPs
[34]. The needle was inserted into a latent MTrP or a
non-MTrP in the upper trapezius at rest and during
contraction. The EMG activities were recorded from the
middle deltoid muscle and the upper, middle, and lower
parts of the trapezius muscle. The intramuscular EMG
activity in the upper trapezius muscle was significantly
higher at rest and during contraction at latent MTrPs
compared with non-MTrPs. Yu et al. measured max-
imum voluntary isometric contraction, endurance, me-
dian frequency, and muscle fatigue index in three groups
of participants: an active MTrP group, a latent MTrP
group, and a control group [35]. The active MTrP group
had a higher median frequency and muscle fatigue index
than the control group. Wytrążek et al. compared the
EMG activity of muscle motor units at rest and maximal
contraction with surface EMG recordings [36]. The re-
sults showed MTrPs correlated with an increase in EMG
amplitude at rest.
Infrared thermography
Infrared thermography can be used to measure the skin
temperature. Dibai-Filho et al. [37] have reviewed the lit-
erature on infrared thermography investigations of
MTrPs. The authors included three comparative studies
[38–40] and one accuracy study [41]. The conclusion of
the review is that the included studies do not agree on
skin temperature patterns in the presence of MTrPs.
The included studies of the review are briefly presented
in the following. Merla et al. [38] found that individuals
with myofascial pain had a greater difference between
the right and left side in skin temperature over the mas-
seter and sternocleidomastoid muscles before and after
maximal voluntary clenching compared to healthy vol-
unteers. They also found that the myofascial pain group
had a greater temperature change over the measured
muscles after maximum voluntary clenching. Kimura et
al. [39] evaluated the vasoconstrictor response after pro-
voking pain in MTrPs with an intramuscular glutamate
injection. Furthermore, they activated the sympathetic
outflow by using a breath-holding maneuver. They
found a decrease in skin temperature over time in latent
MTrPs. In contrast, Zhang et al. [40] did not find that
the skin temperature was affected following an intra-
muscular glutamate injection into latent MTrPs. Haddad
et al. [41] compared infrared thermography and alg-
ometer measurements of MTrPs in the masticatory mus-
cles. The authors found a positive correlation between
skin surface temperature and pressure pain threshold.
Regarding diagnosing MTrPs, infrared thermography
had an accuracy of 0.564 to 0.609 (area under the re-
ceiver operating characteristic curve).
Magnetic resonance imaging
Chen et al. [42] examined 65 patients with myofascial
pain-associated taut bands using magnetic resonance
elastography. They found that agreement between physi-
cians and imaging raters were relatively poor (63%; 95%
CI, 50%–75%), but that these bands could be assessed
quantitatively using magnetic resonance elastography.
The authors suggest that clinicians might overestimate
while magnetic resonance elastography may underesti-
mate MTrPs.
Migraine and myofascial trigger points
Pericranial tenderness in migraine patients was system-
atically described by Jes Olesen in 1978, both during and
outside of attacks [10, 11] leading to speculations that
myofascial mechanisms may be involved in migraine
[12]. The bottom-up model states that increased periph-
eral nociceptive transmission sensitizes the central nervous
system to lower the threshold for perceiving pain while the
top-down model suggests these changes are already
present in the central nervous system [43]. While it can be
argued that pericranial tenderness in migraine may be
caused by a top-down central sensitization, a bottom-up
association was implied in 1981 when Tfelt-Hansen et al.
[44] demonstrated that injections of lidocaine and saline
into tender trigger points could relieve migraine attacks.
They infiltrated the most tender spots of 26 cranial and
neck muscles and tendon insertions in 50 migraine
patients. The most frequent sites of tenderness were
sternocleidomastoid, anterior temporal, neck and shoulder
muscles, the coronoid process and occipital insertions. The
tender points in the mentioned study do not necessarily
overlap with Travell and Simons’ definition of MTrPs, but
the implication stands that peripheral myofascial mecha-
nisms may be involved in migraine pathophysiology. Con-
sequently, there has been an interest in exploring MTrPs
in migraine (Table 1) [45–58].
The occurrence of myofascial trigger points in migraine
Several studies have demonstrated a high occurrence of
active and latent MTrPs in migraine patients [45–49].
Studies show that there is a significantly higher preva-
lence of active MTrPs in migraine patients compared to
healthy controls [45, 46, 58]. There are conflicting re-
sults in which muscles are the most affected [47, 48].
Fernández-de-Las-Peñas et al. [46] observed that active
MTrPs were most prevalent ipsilateral to the migraine
headaches. More unclear is whether the amount of
MTrPs is correlated with the frequency and intensity of
headache attacks. Calandre et al. [45] found a positive
correlation between the number of MTrPs and
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frequency and duration of migraine attacks, whereas two
studies by Ferracini et al. [47, 48] found no such correl-
ation. Interestingly, Landgraf et al. [54] could visualize
MTrPs on MR imaging as focal signal alterations in a
small pilot study.
Neck mobility and specific muscles
There appears to be an association between neck mobility
and MTrPs [46, 48, 49, 58]. Ferracini et al. [48] found that
a higher number of active MTrPs was positively correlated
with a reduction in cervical lordosis and head extension of
the head on the neck. In addition, that lower cervical an-
gles were correlated higher then the number of active
MTrPs. Florencio et al. [49] hypothesized that active
MTrPs in the cervical musculature alters the activity of
the related muscles and that this would be reflected in
EMG readings. They observed that the presence of active
MTrPs in the cervical musculature had different activation
in the neck flexor muscles compared to those without ac-
tive MTrPs in the same muscles regardless of the presence
of pain. Palacios-Ceña et al. [55] found that the number of
active MTrPs in head, neck and shoulder muscles were as-
sociated with widespread pressure hypersensitivity in a
migraine population.
Provocation and intervention studies
Two unblinded studies show that manual palpation of
MTrPs can provoke a migraine attack [45, 53]. Calandre
et al. provoked a migraine attack in one-third of a mi-
graine population by palpating MTrPs [45]. Landgraf et
al. provoked migraine headache by inducing pressure to
MTrPs and could not replicate this by pressure to
non-trigger points in the trapezius in an adolescent mi-
graine population [53].
Interventions targeted at MTrPs show promising re-
sults [50–52, 56, 57], but the quality of studies varies
greatly and lack placebo-control. Giambierardino et al.
demonstrated that local anesthetic infiltration of MTrPs
resulted in a reduction of migraine symptomatology in
terms of frequency and intensity [52]. Furthermore,
there was a reduction of hyperalgesia, not only at the in-
jection site but also in referred areas overlapping with
migraine pain sites. Similar, Ranoux et al. injected botu-
linum toxin in MTrPs with similar results in terms of re-
duction in headache days [56]. Gandolfi et al. improved
the outcome of prophylactic botulinum toxin treatment
in chronic migraine patients with manipulative treat-
ment of MTrPs [50]. The outcome was a lower con-
sumption of analgesics, improvement in pressure pain
threshold and increased cervical range of motion. Like-
wise, Ghanbari et al. reported that combined positional
release therapy targeted at MTrPs with medical therapy
is more effective than the sole pharmacological treat-
ment [51]. Interestingly, sessions of magnetic stimulation
of active MTrPs reduced headache frequency and inten-
sity in adolescent migraineurs [57]. Though these find-
ings need to be verified in a placebo-controlled study.
There has not been any studies on the effect of systemic
musculoskeletal analgesics on MTrPs [59], which would
be of interest for future studies.
Tension-type headache and myofascial trigger points
Both peripheral and central mechanisms have been sug-
gested as important components of TTH [14–16, 60]. Ten-
derness in pericranial myofascial tissue is correlated with
the intensity and frequency of headache [14–16]. Further-
more, there has been demonstrated increased muscle stiff-
ness in the trapezius muscle in TTH patients [17, 18] not
differing between headache and non-headache days [18].
Although a recent study found no increased muscle stiff-
ness in TTH patients, this may be due to the method used
[61]. Studies show that the referred pain elicited by active
MTrPs reproduce the headache pattern in TTH patients
[62–66]. Accordingly, there has been an interest in investi-
gating the occurrence of MTrPs in TTH (Table 2) [62–80].
The occurrence of myofascial trigger points in tension-type
headache
There is a high occurrence of active and latent MTrPs in
patients with TTH [63–67, 69–72, 79] Active MTrPs are
found almost only in TTH patients compared to con-
trols [63, 65, 69, 72, 80]. MTrPs are more prevalent on
the dominant side of the patients [66]. The number of
active MTrPs is higher in adults in comparison to ado-
lescents regardless of no significant association between
the number of active MTrPs and headache frequency,
duration and intensity [62]. Other studies have found
that active MTrPs are correlated with the severity of
TTH [65, 67, 78, 80] with a greater occurrence of MTrPs
in chronic TTH in comparison to episodic TTH [80].
Furthermore, studies show that active MTrPs are corre-
lated with the intensity, duration and frequency of head-
ache episodes in TTH [65, 80]. In contrast, other studies
failed to show a correlation between MTrPs and chronic
and frequent episodic TTH [78] and showed no correl-
ation between MTrPs and headache parameters either in
episodic TTH patients [69].
Neck mobility and specific muscles
Episodic TTH patients had less neck mobility compared
to controls [69]. Patients with active MTrPs had a greater
forward head position than subjects only with latent
MTrPs [69]. However, neither forward head position or
neck mobility was correlated with headache parameters
[69]. In a different study, active MTrPs in the right upper
trapezius muscle and left sternocleidomastoid muscle was
correlated with a greater headache intensity and duration
[72]. Furthermore, active MTrPs in the right and left
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temporalis muscles correlated with longer headache dur-
ation and greater headache intensity, respectively [72].
Suboccipital active MTrPs correlated with increased in-
tensity and frequency of headache [65]. Chronic TTH pa-
tients with active MTrPs in the analyzed muscles had a
greater forward head position than those subjects only
with latent MTrPs [65, 72]. Sohn et al. [80] identified a
greater occurrence of MTrPs in chronic TTH compared
to episodic TTH and that the number of active MTrPs
correlated with the frequency and duration of headache,
although they did not find any correlations for forward
head posture and neck mobility in contrast to Fernández--
de-las-Peñas et al. [65, 72].
Pressure pain threshold
The number of active and latent MTrPs was signifi-
cantly and negatively associated with pressure pain
thresholds on the temporalis muscle, C5/C6 zygapo-
physeal joint, second metacarpal, and tibialis anterior
muscle [78]. Thus, a higher number was associated
with a more generalized sensitization regardless of the
frequency of headache. Another study observed that
the location of active MTrPs in the temporalis muscle
corresponded to areas with lower pain pressure
thresholds which establishes a relationship between
the two [68]. The same group found that chronic
TTH patients with bilateral active MTrPs in the tra-
pezius muscles have a significantly lower pain pres-
sure threshold compared to patients with only
unilateral active MTrPs [70]. Minimum clinical differ-
ences in pressure pain thresholds in TTH patients
may be used to evaluate treatment of MTrPs [79].
Therapeutic studies targeting myofascial trigger points
Karadas et al. [81] investigated pericranial lidocaine
injections in MTrPs in 108 patients with frequent epi-
sodic TTH using a double-blind placebo-controlled
randomized study design. Repeated local lidocaine
injections into the MTrPs in the pericranial muscles
reduced both the frequency and intensity of pain
compared to placebo. Another placebo-controlled study
found similar results with lidocaine injections in MTrPs in
chronic TTH with a reduction in pain frequency, pain in-
tensity, and analgesic use [74]. In addition, there was a sig-
nificant effect on anxiety and depression of the subjects. A
randomized, double-blind, placebo-controlled pilot study
of botulinum toxin A injections in MTrPs included 23 pa-
tients with chronic TTH [73]. The subjects were assessed
at 2 weeks, 1, 2 and 3 months after injection. The botu-
linum toxin A group reported a reduction in headache fre-
quency that disappeared by week 12. There was no
difference in intensity between the groups. In a random-
ized, placebo-controlled clinical trial, Moraska et al. ap-
plied massage focused on MTrPs of patients with TTH
[77]. For both active and placebo groups, there was a de-
crease in headache frequency, but not for intensity or dur-
ation. Thus, there was no difference between massage and
placebo [81].
Discussion
Ultrasound and EMG appear to be the most promis-
ing modalities to be used as a diagnostic test for
MTrPs. While the use of ultrasound in headache dis-
orders has primarily been focused on vascular
changes and not on myofascial structures [82], ultra-
sound may also be used to identify MTrPs if specific
analysis methods are applied [29] or with the use of
elastography [27, 30, 32]. However, there is no precise
description of a gold standard using these techniques,
and they have yet to be evaluated in headache pa-
tients. Active MTrPs affect the electrical activity at
rest and during muscle contraction in EMG studies
[33–36]. Out of the two modalities, ultrasound is pre-
sumably the most viable candidate as a diagnostic test
as it has an immediate availability at most treatment
sites, it is time-efficient and is non-invasive. Although
there are currently no studies investigating if it is
possible to identify MTrPs with ultrasound without
prior manual palpation. Future studies should investi-
gate if ultrasound is comparable with manual palpa-
tion in identifying MTrPs. The other modalities do
not appear to be suitable as microdialysis show mixed
results regarding whether the local milieu of MTrPs
is changed and needs further exploration before a
conclusion can be made [25, 26, 83]. According to
the review by Dibai-Filho et al. [37], infrared therm-
ography appears to be a promising non-invasive
method, but it should still only be used as an auxil-
iary tool in the evaluation of MTrPs due to conflict-
ing results. Magnetic resonance elastography in
diagnosing MTrPs has only been investigated in a few
studies, and the sensitivity may be too low for suit-
able use as a diagnostic test [42].
Studies show a high occurrence of active and latent
MTrPs [45–49] and correlation between neck mobility
and MTrPs in migraine patients [46, 48, 49, 58]. How-
ever, there are conflicting results in which muscles are
the most affected [47, 48], and it is unclear whether
there is a positive correlation with the degree of head-
ache frequency or intensity due to conflicting results.
Palpation of MTrPs may provoke a migraine attack in
some patients [45, 53] but needs further confirmation
in placebo-controlled studies. Intervention studies tar-
geting MTrPs are mostly positive [50–52, 56, 57], but
they lack placebo-control. Thus, a bottom-up associ-
ation between MTrPS and migraine [44] cannot be fully
supported based on the evidence (Fig. 1). In addition,
in patients with migraine-fibromyalgia comorbidity, it
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has been shown that migraine attacks exacerbate fibro-
myalgia symptoms, suggesting a top-down central
sensitization [84] as fibromyalgia symptoms include
specific tender points [85]. Although a study showed
migraine severity was similar in migraine patients with
and without fibromyalgia [86]. One would expect an as-
sociation between migraine severity and co-existing
fibromyalgia if a top-down central is taking place in
patients with this comorbidity. It is possible that
MTrPs may have an important role in some subpopu-
lations of migraine patients. This calls for therapeutic
studies targeting patients with a high degree of
MTrPs, but this is only speculative at this point.
The prevalence of active MTrPs in TTH [65–67, 73,
74, 77, 78, 80, 81] is coherent with the hypothesis that
peripheral mechanisms are involved in the pathophysi-
ology of TTH [14–16, 60]. It has been speculated that
an increased peripheral nociception increases the
sensitization of central mechanisms resulting in an in-
crease in the sensitivity to peripheral pain (Fig. 1). Ac-
tive MTrPs may contribute to a central sensitization as
they are correlated with lower pain pressure thresholds
[68, 70, 78]. This would also provide an explanation
for the efficacy of injections of lidocaine in MTrPs [74,
81] as these would reduce the transmission of periph-
eral nociception. However, these assumptions are in
contrast with a study showing that the number of ac-
tive MTrPs is higher in adults in comparison to adoles-
cents, regardless of no significant association with
headache parameters [62]. This suggests that active
MTrPs are accumulated over time as a consequence of
TTH [62] instead of being an integrated part of the
pathophysiology of TTH. Previous studies of botu-
linum toxin A injections in pericranial muscles have
been shown to have no effect in TTH [87]. The efficacy
of botulinum toxin A in MTrPs [73] might be ex-
plained by its possible action of modulating the release
of nociceptive and inflammatory mediators e.g., CGRP
and SP [88]. These inflammatory mediators may be in-
creased in the local milieu of MTrPs [25, 26]. This
would also account for its poor efficacy in injection
protocols targeting fixed landmarks in pericranial mus-
cles instead of MTrPs [87], as these substances appear
to be concentrated at MTrPs [25, 26].
There are many overlapping findings in studies of
MTrPs in migraine or TTH. In both disorders, MTrPs
are prevalent and may be related to neck mobility. Pal-
pation of MTrPs can, in some cases, provoke an attack
in migraine patients, while palpation of MTrPs in TTH
can provoke pain resembling the usual headache pat-
tern of patients. Intervention studies are promising in
both disorders. The quality of studies in both disorders
varies greatly as many of the reviewed studies lacked
blinding (Table 3). Furthermore, true blinding is diffi-
cult to achieve as active MTrPs by definition cause re-
ferred pain.
Conclusion
In conclusion, ultrasound elastography is the most
promising tool to assess MTrPs [27, 30, 32], but still
needs to be performed combined with palpation,
which introduces risk of bias and interobserver vari-
ation. MTrPs are very frequent in both migraine pa-
tients [45–49] and TTH patients [65–67, 73, 74, 77,
78, 80, 81] compared to healthy controls. Active
Table 3 An overview on the use of blinding, control groups and placebo
Migraine Tension-type headache Total
Blinding 36% (5/14 relevant studies) 79% (15/19 relevant studies) 61% (19/33 relevant studies)
Control group 44% (4/9 relevant studies) 79% (11/14 relevant studies) 65% (15/23 relevant studies)
Placebo 40% (2/5 relevant studies) 80% (4/5 relevant studies) 60% (6/10 relevant studies)
Fig. 1 The bottom-up model states that increased peripheral
nociceptive transmission sensitizes the central nervous system to lower
the threshold for perceiving pain while the top-down model suggests
these changes are already present in central nervous system. In relation
to myofascial trigger points, a bottom-up model would suggest that
increased nociceptive transmission from myofascial trigger points lowers
the threshold for perceiving pain (red). A top-down model would
suggest that central sensitization may contribute to the occurrence of
myofascial trigger points rather than the other way around (blue)
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MTrPs are especially interesting as these are rarely
found in control groups. However, their role in the
pathophysiology of each disorder and to which degree
is still unclear. The results of the provocation and
intervention studies support the hypothesis of a
trigemino-cervical-complex pathophysiology model in
both migraine [45, 50–53, 56, 57] and TTH [73, 74, 81].
Whether MTrPs contribute to an increased disease bur-
den in migraine is uncertain [45, 47, 48] and needs further
exploration [50, 52]. Future research should aim to in-
crease the quality of studies before further speculations
are made. To elucidate this, large-scale studies to stratify
the headache populations into more homogenous sub-
groups should be conducted.
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